Robert A Hauser
Overview
Explore the profile of Robert A Hauser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
255
Citations
6254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fernandez H, Macklin E, Hauser R, Chou K, Cakmak Y, Ozsoy B, et al.
Parkinsonism Relat Disord
. 2024 Jan;
121:105959.
PMID: 38246833
Background: Studies have suggested that intrinsic auricular muscle zones (IAMZ) stimulation alleviates motor features of Parkinson disease (PD). Methods: A randomized, blinded, active sham-controlled pilot trial was conducted to evaluate...
12.
Espay A, Hauser R, Dhall R, Thakkar S, Cloud L, Zeitlin L, et al.
Mov Disord
. 2023 Dec;
39(2):428-432.
PMID: 38111267
Background: IPX203 is a novel oral extended-release formulation of carbidopa/levodopa (CD/LD) developed to address the short half-life of immediate-release CD/LD. In the phase 3 RISE-PD trial, IPX203 significantly improved "Good...
13.
Olanow C, Hauser R, Burdick D, Dhall R, de Marcaida J, Gil R, et al.
Mov Disord
. 2023 Oct;
39(2):350-359.
PMID: 37886872
Background: There remains uncertainty as to the optimal way to initiate therapy for Parkinson's disease (PD) to maximize benefit and minimize adversity. Objectives: The objective was to determine if P2B001...
14.
Hauser R, Espay A, Ellenbogen A, Fernandez H, Isaacson S, LeWitt P, et al.
JAMA Neurol
. 2023 Aug;
80(10):1062-1069.
PMID: 37578800
Importance: Levodopa has a short half-life and a limited window of opportunity for absorption in the proximal small intestine. IPX203 is an oral, extended-release formulation of carbidopa-levodopa developed to address...
15.
Isaacson S, Hauser R, Pahwa R, Gray D, Duvvuri S
Clin Park Relat Disord
. 2023 Jul;
9:100212.
PMID: 37497384
Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson's disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and...
16.
Martino D, Karnik V, Bhidayasiri R, Hall D, Hauser R, Macerollo A, et al.
Mov Disord
. 2023 Apr;
38(6):1008-1026.
PMID: 37081740
Background: Antipsychotic-associated movement disorders remain common and disabling. Their screening and assessment are challenging due to clinical heterogeneity and different use of nomenclature between psychiatrists and neurologists. Objective: An International...
17.
Hauser R, Ondo W, Zhang Y, Bowling A, Navia B, Pappert E, et al.
J Parkinsons Dis
. 2023 Mar;
13(3):403-414.
PMID: 36970914
Background: Nausea is common upon initiating dopamine agonists in patients with Parkinson's disease (PD); however, pretreatment with an antiemetic is recommended only when initiating apomorphine formulations. Objective: Evaluate the need...
18.
Hauser R, LeWitt P, Waters C, Grosset D, Blank B
Clin Neuropharmacol
. 2023 Jan;
46(2):66-78.
PMID: 36715241
Oral levodopa is the most effective treatment for Parkinson disease, but OFF periods emerge over time. Gastrointestinal dysfunction and food effects impact levodopa absorption, contributing to unpredictable control of OFF...
19.
Soileau M, Aldred J, Budur K, Fisseha N, Fung V, Jeong A, et al.
Lancet Neurol
. 2022 Nov;
21(12):1099-1109.
PMID: 36402160
Background: Levodopa is the most effective symptomatic therapy for Parkinson's disease, but patients with advanced Parkinson's disease develop motor fluctuations with chronic oral levodopa therapy. Foslevodopa-foscarbidopa is a soluble formulation...
20.
Camilleri M, Subramanian T, Pagan F, Isaacson S, Gil R, Hauser R, et al.
Ann Intern Med
. 2022 Nov;
175(12):1666-1674.
PMID: 36343348
Background: Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhibits the formation of αS aggregates and improved constipation in an open-label study in patients with...